Such trials should use harmonized severity measures and incorporate mechanistic endpoints—such as microbiome profiling, inflammatory biomarkers, and IGF-1/mTOR signaling assays—to clarify the pathways through which probiotics may influence acne. The gene discussed is MTOR; the disease is acne.